All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

MRD-Guided Zanubrutinib/Venetoclax/Obinutuzumab Triplet Induces Deep Remissions in R/R CLL

April 16th 2025

Zanubrutinib plus venetoclax and obinutuzumab was well tolerated—aside from COVID-19–related toxicities—in patients with relapsed/refractory CLL.

Targeted Therapies Both Refine and Raise Questions About CRPC Treatment Decision-Making

April 16th 2025

Evan Y. Yu, MD, discusses PARP inhibitor treatment selection and sequencing for patients with metastatic castration-resistant prostate cancer.

Encorafenib/Cetuximab Plus mFOLFOX6 Provides New SOC for BRAF V600E+ mCRC

April 16th 2025

Scott Kopetz, MD, PhD, FACP, highlights the efficacy of encorafenib/cetuximab with mFOLFOX6 in BRAF V600E–mutated metastatic colorectal cancer.

Molecular Profiling, Endocrine Sensitivity Are Key to Managing Later-Line HR+/HER2-Negative Breast Cancer

April 16th 2025

Erika P. Hamilton, MD, discusses the current role of CDK4/6 inhibitors and evolving targeted therapies in advanced HR-positive, HER2-negative breast cancer.

Dana-Farber Researchers Receive AACR 2025 Scientific Achievement Awards

April 16th 2025

Three researchers from Dana-Farber Cancer Institute have been selected by the American Association for Cancer Research (AACR) as recipients of 2025 Scientific Achievement Awards.

TLX101 Has Preliminary Safety and Clinical Activity in Recurrent High-Grade Glioma

April 16th 2025

TLX101 was associated with a favorable safety profile and preliminary signs of clinical activity in patients with recurrent high-grade glioma.

NDA Accepted in China for Zurletrectinib for NTRK Gene Fusion+ Advanced Solid Tumors

April 16th 2025

A new drug application for zurletrectinib has been accepted in China for the treatment of patients with NTRK gene fusion–positive advanced solid tumors.

RCC Treatment Decision-Making Requires a Balance of Efficacy and Individual Patient Considerations

April 16th 2025

Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for renal cell carcinoma.

Pembrolizumab-Based Regimens Gain Ground in TNBC Management

April 16th 2025

Nerea Lopetegui-Lia, MD, discusses the prevalence of and risk factors for triple-negative breast cancer, and strategies that may improve survival outcomes.

CCTG BR.31 Data Show Adjuvant Durvalumab Does Not Alter Relapse Frequency or Patterns in Resected NSCLC

April 16th 2025

Adjuvant durvalumab was not associated with a reduction in the frequency of relapse in NSCLC.

FDA-Approved Isotope Therapies Provide 2 Options in the Castration-Resistant Prostate Cancer Armamentarium

April 15th 2025

Yung Lyou, MD, discusses FDA-approved isotope therapies and the development of novel therapies in the castration-resistant prostate cancer space.

Nivolumab-Based, Response-Adapted Approach Yields Durable Responses in Frontline Follicular Lymphoma

April 15th 2025

Response-adapted treatment with nivolumab with or without rituximab produced responses in treatment-naive follicular lymphoma.

PARP Inhibitor Rechallenge With Niraparib Plus Bevacizumab Is Feasible, Active in Recurrent Ovarian Cancer

April 15th 2025

Hyun-Woong Cho, MD, PhD, highlights the efficacy of niraparib/bevacizumab as maintenance therapy in platinum-sensitive, recurrent ovarian cancer.

Ibrutinib/Lenalidomide/Rituximab Yields Long-Term Efficacy in R/R MCL

April 15th 2025

Treatment with the IR2 regimen led to durable responses that were favorable compared with those in chemotherapy-treated relapsed/refractory MCL.

FDA Receives sBLA for Nogapendekin Alfa Inbakicept in Papillary NMIBC

April 15th 2025

A sBLA for nogapendekin alfa inbakicept in BCG-unresponsive non–muscle-invasive bladder cancer with papillary disease was submitted to the FDA.

Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

April 15th 2025

The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.

Clinical Trial Opens for Patients With High-Grade Neuroendocrine Cancer

April 15th 2025

Sylvester Comprehensive Cancer Center has opened a clinical trial for patients with high-grade neuroendocrine cancers evaluating an oncolytic virus.

Enhanced Dermatologic AE Prophylaxis Is Effective in EGFR-Mutated Advanced NSCLC

April 15th 2025

Enhanced dermatologic management lowered rates of dermatologic AEs during first-line amivantamab/lazertinib treatment for EGFR-mutated advanced NSCLC.

BTK Inhibitor Refractoriness and Platelet Count Are Prognostic for Survival With Brexu-Cel in MCL

April 14th 2025

Patients with MCL who received real-world brexu-cel experienced lower survival when they were BTK inhibitor refractory and/or had lower platelet counts.

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT

April 14th 2025

Daratumumab plus lenalidomide maintenance improved clinical outcomes vs lenalidomide monotherapy in multiple myeloma after transplant.